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ABSTRACT
Objectives We investigated whether citrullinated
tenascin-C (cTNC), an extracellular matrix protein
expressed at high levels in the joints of patients with
rheumatoid arthritis (RA), is a target for the
autoantibodies in RA.
Methods Citrullinated sites were mapped by mass
spectrometry in the fibrinogen-like globe (FBG) domain
of tenascin-C treated with peptidylarginine deiminases
(PAD) 2 and 4. Antibodies to cyclic peptides containing
citrullinated sites were screened in sera from patients
with RA by ELISA. Potential cross-reactivity with well-
established anticitrullinated protein antibody (ACPA)
epitopes was tested by inhibition assays. The
autoantibody response to one immunodominant cTNC
peptide was then analysed in 101 pre-RA sera (median
7 years before onset) and two large independent RA
cohorts.
Results Nine arginine residues within FBG were
citrullinated by PAD2 and PAD4. Two immunodominant
peptides cTNC1 (VFLRRKNG-cit-ENFYQNW) and cTNC5
(EHSIQFAEMKL-cit-PSNF-cit-NLEG-cit-cit-KR) were
identified. Antibodies to both showed limited cross-
reactivity with ACPA epitopes from α-enolase, vimentin
and fibrinogen, and no reactivity with citrullinated
fibrinogen peptides sharing sequence homology with
FBG. cTNC5 antibodies were detected in 18% of pre-RA
sera, and in 47% of 1985 Swedish patients with RA
and 51% of 287 North American patients with RA. The
specificity was 98% compared with 160 healthy controls
and 330 patients with osteoarthritis.
Conclusions There are multiple citrullination sites in
the FBG domain of tenascin-C. Among these, one
epitope is recognised by autoantibodies that are
detected years before disease onset, and which may
serve as a useful biomarker to identify ACPA-positive
patients with high sensitivity and specificity in
established disease.
INTRODUCTION
Citrullination, the conversion of arginine residues
to the non-standard amino acid citrulline, is cata-
lysed by peptidylarginine deiminases (PAD). Levels
of citrullinated proteins are significantly elevated
at sites of inflammation including the joints of
patients with rheumatoid arthritis (RA).1 2
Whereas citrullination is ubiquitous in normal
physiology and inflammation, anticitrullinated
protein antibodies (ACPAs) are well established
markers for the diagnosis of RA.3 4 Appearing
before evident symptoms, these autoantibodies
correlate with poor prognosis and progressive
joint destruction,5–8 and ACPA-positive patients
often require more aggressive treatment.9
ACPAs are routinely detected using cyclic-
citrullinated peptide (CCP) assays, designed to
capture ACPA with maximum diagnostic sensitivity
and specificity, using artificial peptides with no hom-
ology to naturally occurring proteins in the joint.
While an excellent diagnostic test, these assays are of
limited use in defining subsets of ACPA-positive
patients and examining mechanisms of disease
pathogenesis. At least 20 molecules recognised by
ACPA have been described,10 but few of these have
been demonstrated in the joint, epitope-mapped,
antigen specificity confirmed and evaluated in inde-
pendent large cohorts. Antigenic peptides described
so far that fulfil all of these criteria include citrulli-
nated fibrinogen (cFib),11 citrullinated vimentin
(cVim),12 and citrullinated α-enolase peptide 1
(CEP-1).13 The diagnostic sensitivity of each of these
peptides is relatively low, typically between 30% and
50%. However, when analysed in combination, sen-
sitivity increases, and multiple serological subsets are
demonstrated.14 Moreover, knowledge of the
antigen specificity enables investigation of aetio-
logical mechanisms. For example gene/environment
(MHC shared epitope and smoking) interactions
have been demonstrated with anti-CEP-115 particu-
larly when combined with dual positivity for
anti-cVim.14 Knowledge of the antigens involved
also reveals how ACPAs contribute to disease patho-
genesis. For example, immune complexes containing
cFib signal to induce proinflammatory cytokines,16 17
and antibodies to cVim provoke osteoclastogenesis
and bone erosion.18
Tenascin-C is a large, multimodular, extracellular
matrix glycoprotein that is specifically upregulated
during inflammation, but which is absent in most
healthy tissues.19 20 Tenascin-C levels are elevated
in the cartilage, synovium and synovial fluid of
patients with RA,21–24 as well as in RA serum where
levels correlate with joint erosion.25 Tenascin-C sti-
mulates inflammation; inducing de novo cytokine
synthesis via activation of toll-like receptor 4
(TLR4),26 controlling cytokine synthesis post-
transcriptionally via induction of microRNAs27 and
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regulating adaptive immunity by driving Th17 cell polarisa-
tion.28 29 In murine models of arthritis tenascin-C expression is
required to maintain chronic joint inflammation and the
C-terminal fibrinogen-like globe domain (FBG) of tenascin-C is
arthritogenic upon intra-articular injection.19
Tenascin-C can be found in immune complexes in the RA
joint.30 Moreover, a citrullinated peptide from the FBG domain
of tenascin-C was recently detected in RA synovial fluid.31
These data prompted us to investigate this arginine-rich domain
of tenascin-C as a novel autoantigen. To characterise it with the
criteria that have been applied to cFib, cVim and CEP-1, we
epitope-mapped the FBG domain with a screening panel of RA
sera, and examined the antigen specificity of two immunodomi-
nant epitopes by inhibition studies. We then went on to stand-
ardise an ELISA assay and used it to detect antibodies in pre-RA
serum samples and two large independent patient cohorts with
early and established RA.
MATERIAL AND METHODS
Subjects
All RA cases fulfilled the 1987 American College of Rheumatology
classification criteria.32 Four cohorts were examined, all from pre-
viously published studies with informed consent and ethical
approval. (1) The screening cohort comprised 20 British patients
with RA and 20 healthy individuals.13 (2) The 101 pre-RA cases
and 326 matched controls were identified in a nested case-control
study in four Southern European cohorts.33 (3) One thousand
nine hundred and eighty-five cases of RA and 160 controls were
from the Swedish population-based case-control study EIRA
(Epidemiological Investigation of RA).34 Details of this EIRA
cohort can be found in the online supplementary file. (4) Two
hundred and eighty-seven patients with RA and 330 control
patients with osteoarthritis (OA) were from the USA.35
Citrullination reaction
Recombinant human FBG26 was incubated with rabbit skeletal
muscle PAD2 (rPAD2), or recombinant human PAD2 or PAD4
(hPAD2, hPAD4), resolved on an SDS gel and stained with
Coomassie-blue or western blotted with a monoclonal human
antimodified citrulline (AMC) antibody (Modiquest Research,
clone C4, 1:500). A detailed description of this method can be
found in the online supplementary file.
LC-MS/MS analyses
Citrullinated FBG was resolved on a 12% SDS gel and
Coomassie-stained protein bands were excised and in gel-
digestion performed as described.36 Peptides were analysed by
LC-MS/MS. Details of this method can be found in the online
supplementary file.
Differential scanning fluorimetry and circular dichroism
Details can be found in the online supplementary file.
Peptides, ELISAs and cross-reactivity assay
Details about peptides can be found in the online supplemen-
tary file. ELISAs were used to detect antibodies against citrulli-
nated peptides in human sera as described.13 Briefly, 96-well
plates were coated with 10 μg/mL peptide, blocked with 2%
BSA and incubated with sera diluted 1:100. Bound antibodies
were detected with an HRP conjugated antihuman IgGFc mono-
clonal antibody ( Jackson—for EIRA study, Stratech—for all
other ELISAs). A standard curve of positive sera was used to cal-
culate relative antibody titres in arbitrary units (AU) for each
sample. Subtraction of the OD450 of the native peptide from
the OD450 of the citrullinated peptide was used to correct
reactivity and dOD450 values were transformed into AU using
the standard curve (dAU). The cross-reactivity assay is described
in the online supplementary file.
Statistical analysis and software
Details can be found in the online supplementary file.
RESULTS
FBG is citrullinated in vitro by PAD2 and PAD4
FBG was citrullinated by rPAD2, demonstrated by a small
increase in the molecular weight on Coomassie-stained
SDS-PAGE and western blotting with an AMC antibody (figure
1A,B). Mass spectrometry analysis of citrullinated FBG covered
14 of the 17 arginines present in this domain of tenascin-C, of
which 9 were citrullinated (figure 1C, see online supplementary
figure S1). rPAD2, hPAD2 and hPAD4 each citrullinated the
same sites within FBG with no major difference in the degree of
citrullination observed (see online supplementary figure S2).
Circular dichroism showed comparable spectra between native
FBG and citrullinated FBG (figure 1D) indicating that citrullina-
tion of FBG does not impact the secondary structure of the
protein. Differential scanning fluorimetry however revealed a
significantly lower melting temperature of citrullinated FBG
(46.5±0.2) compared with FBG (54.3±0.1) (figure 1E), demon-
strating that citrullination leads to partial protein unfolding.
cTNC1 and cTNC5 are the primary epitopes recognised by
ACPA in patients with RA
Five tenascin-C cyclic peptides encompassing the citrullinated
residues identified by mass-spectrometry, together with their
arginine-containing controls (see online supplementary table
S1), were used to map antibody response in a screening panel of
serum samples from 20 patients with RA, and from 20 healthy
subjects, by ELISA. Antibodies to citrullinated tenascin-C
(cTNC) peptides cTNC1 and cTNC5 were detected in serum
samples from 35% and 40% of patients, respectively, but not in
control sera, with no response against the arginine-containing
control peptides (rTNC). There was little or no reactivity with
the other three peptides tested (figure 2). Therefore cTNC1 and
cTNC5 were selected for further study.
Anti-cTNC antibodies show limited cross-reactivity with
other ACPA epitopes
To examine epitope specificity and potential cross-reactivity of
anti-cTNC antibodies with already identified ACPA antigens,
inhibition experiments were performed with the well defined
peptides of CEP-1 (5KIHA-cit-EIFDS-cit-GNPTVE21), cVIM
(59VYAT-cit-SSAV-cit-L-cit-SSVP74) and cFIBβ (36NEEGFFSA-cit-
GHRPLDKK52). Absorption by the homologous peptides was
more efficient for cTNC5 than cTNC1. There was no cross-
reactivity between anti-cTNC1 and cVIM and cFIBβ, though
there was some inhibition by the CEP-1 peptide (17–70% inhib-
ition) (figure 3A). In contrast, there was no cross-reactivity
between anti-cTNC5 and CEP-1, while these antibodies showed
limited cross-reactivity with cVIM and cFIBβ in one serum
sample (inhibition by 58% and 50%, respectively) (figure 3B).
Because the FBG domain of tenascin-C exhibits some sequence
homology with fibrinogen we also analysed whether anti-cTNC
antibodies cross-react with epitopes on citrullinated peptides
containing similar sequences of fibrinogen β chain (cFibβ281–296)
and fibrinogen γ chain (cFibβ474–491, cFibγ409–426) (figure 4A,
for peptide sequences see online supplementary table S2). From
17 sera reactive with cTNC1, 7 also reacted with cFibβ281–296
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(figure 4B), from 19 sera reactive with cTNC5, 14 also reacted
with cFibβ474–491, and 9 with cFibγ409–426 (figure 4C). To
examine whether this dual positivity was due to true cross-
reactivity, four samples that were double positive for cTNC and
cFib peptide IgG were tested by inhibition experiments. No
reduced reactivity to cFBG epitopes was observed when sera
were preincubated with cFibβ and cFibγ peptides (figure 4D).
Anti-cTNC5 is detected in pre-RA sera and with
moderate-to-high sensitivity in early and established RA
In 101 pre-RA sera (median 7 years before diagnosis), 18% of
pre-RA sera were positive for anti-cTNC5 antibodies (figure 5A)
compared with 2% of 326 sera from controls. No antibodies
against cTNC1 were detected (data not shown). Therefore,
because cTNC5 appeared to have better antigen specificity in
our absorption experiments and a higher frequency of anti-
bodies in pre-RA and established RA, further analysis focused
on cTNC5.
In the EIRA cohort, 47% of 1985 RA sera and 2% of 160
healthy control sera were positive for antibodies to cTNC5,
indicating a diagnostic sensitivity of 47% and specificity of
98%. Within the RA sera, 2.5% also bound the arginine-control
peptide rTNC5 (figure 5B), and when controlling for binding to
the arginine control peptide the sensitivity remained moderately
high at 41% (figure 5C). This figure was higher than the fre-
quency of citrulline-specific antibodies to CEP-1 (35%),
Figure 1 Citrullination of fibrinogen-like globe (FBG) by rPAD2. Coomassie stained SDS gels (A) and immunoblot probed with an antimodified
citrulline (AMC) antibody (B) of FBG citrullinated by rPAD2. FBG incubated in buffer with rPAD2 but without Calcium (-Ca2+) or without enzyme
(-PAD) served as negative controls. Untreated native FBG was loaded in the last well. (C) Arginine residues citrullinated by rPAD2, hPAD2 and
hPAD4 were determined by LC-MS/MS. Arginine residues that were modified to citrulline are highlighted in blue, all non-citrullinated arginines are
shown in green. (D) The super secondary structure of native and citrullinated FBG (3 h, 20U rPAD2/mg FBG) was analysed by circular dichroism. (E)
The melting temperature of native and citrullinated FBG (3 h, 20U rPAD2/mg FBG) was analysed by differential scanning fluorimetry. Results are
shown as mean ±SD from three independent experiments.
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anti-cVIM (37%) and anti- cFIBβ (37%), measured in the same
cohort by ELISA.14
We confirmed the moderate-to-high diagnostic sensitivity of
cTNC5 (51%) in an independent US cohort of 287 sera from
patients with RA and 330 sera from OA disease controls (figure
5D). In this cohort the binding to rTNC5 was not increased
compared with OA.
Anti-cTNC5 reactivity was significantly higher in CCP2-posi-
tive patients compared with CCP2-negative patients in RA (figure
6A,B) and pre-RA samples (figure 6C). Anti-cTNC5 antibody
largely overlapped with other ACPA (figure 6D,E, see online sup-
plementary figure S3) in the RA and pre-RA cohorts. However in
the EIRA cohort 5.4% of the serum samples exclusively reacted
with the cTNC5 peptide alone. In the anti-CCP2 negative
samples 4.9% reacted with cTN5.
In EIRA cTNC5-positive RA was associated with smoking (OR
1.65 vs 1.26) and HLA-DRB1 shared epitopes (OR 4.98 vs 1.68),
but not with PTPN22 (OR 1.77 vs 1.44) when compared with
the cTNC5-positive/CCP2-negative RA subset (see online supple-
mentary table S3). We also analysed whether cTNC5 antibodies
are associated with specific HLA-DRB1 epitopes and found that
cTNC5 antibodies did not associate with DRB1*10 alleles, but
with HLA-DRB1*01 and DRB1*04 alleles (see online supple-
mentary table S4). Antibodies against cTNC5 negatively asso-
ciated with HLA-DR13 (see online supplementary table S5).
In the US cohort, cTNC5 antibody positivity was significantly
associated with disease activity (DAS 28-CRP), but did not asso-
ciate with other analysed clinical parameters (disease duration,
swollen and tender joints, sharp score and erosion score) (see
online supplementary table S6).
Figure 2 Identifying the citrullinated antibody epitope. IgG response to citrullinated fibrinogen-like globe (FBG) peptides (cTNC) and arginine
containing control peptides (rTNC) in patients with rheumatoid arthritis (RA; n=20) and healthy controls (HC, n=20). Mann-Whitney U test was used
to calculate p values for differences between groups (ns=no significant difference, *p<0.05 and **p<0.01, ***p<0.001, ****p<0.001). cTNC,
citrullinated tenascin-C.
Figure 3 Anti-cTNC antibody cross-reactivity with CEP-1, cVIM and cFIBβ. Sera, double-reactive with peptides cTNC1 or cTNC5 and CEP-1, cVIM or
cFIBβ, respectively, were preincubated with increasing concentrations of the indicated peptides, and the IgG response to cTNC1 (A) and cTNC5 (B)
was measured. CEP-1, citrullinated α-enolase peptide 1; cFib, citrullinated fibrinogen; cTNC, citrullinated tenascin-C; cVim, citrullinated vimentin.
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DISCUSSION
In this study, we describe a novel citrullinated peptide from the
FBG domain of tenascin-C. The citrullinated residues can be
generated by either PAD2 or PAD4, yielding epitopes that are
recognised by antibodies in approximately one of every five
individuals with preclinical RA and with a moderate-to-high
diagnostic sensitivity in early and established disease. Inhibition
assays and analysis of antibodies to other well characterised pep-
tides indicate that anti-cTNC5 antibody status is independent of
reactivity to other citrullinated peptides. Even though a large
number of antigenic citrullinated peptides have been described
as reactive with ACPA in previous reports, few have been exam-
ined with the stringent criteria used in this study. Therefore, our
findings suggest that cTNC5 is a novel and independent add-
ition to the relatively small number of citrullinated peptides
which are genuinely targeted by ACPA, and which may have a
role in clinical diagnosis and investigating pathogenesis in RA.
The FBG domain of tenascin-C was citrullinated in vitro by
PAD2 and PAD4. While these enzymes have different substrate
specificities,37 both modified the same nine arginines in FBG to
Figure 4 Anti-cTNC antibody cross-reactivity with homologous fibrinogen peptides. (A) Multiple sequence alignment (Clustal Omega) of
tenascin-C, fibrinogen β chain and fibrinogen γ chain. Arginines found citrullinated in vitro are highlighted in red, citrullinated arginines described
as anticitrullinated protein antibody (ACPA) epitopes are underlined. (B and C) IgG response to cTNC1, cTNC5 and homologous cFib peptides was
measured in sera positive for cTNC1 (B) or cTNC5 (C). (D) Sera, double-reactive to peptides cTNC1 or cTNC5 and the homologous cFib peptides were
preincubated with increasing concentrations of the indicated peptides, and IgG response to cTNC1 and cTNC5 was measured. cFib, citrullinated
fibrinogen; cTNC, citrullinated tenascin-C; HC, healthy controls; RA, rheumatoid arthritis.
Figure 5 Anti-cTNC5 antibody response in rheumatoid arthritis (RA) and pre-RA sera. IgG response to cTNC5 and rTNC5 in serum samples from
(A) 101 pre-RA individuals (pre-RA) and 326 controls, and (B) from 1985 patients with RA (RA) and 150 healthy controls (HC) from the
Epidemiological Investigation of RA (EIRA) cohort. (C) IgG response to cTNC5 in the EIRA cohort in dAU when controlled for binding to arginine
control peptide. dAU was calculated as described in Material and Methods. (D) IgG response to cTNC5 and rTNC5 in 287 serum samples from
patients with RA (RA) and 330 serum samples from patients with osteoarthritis (OA) from a US cohort. The red line indicates the mean. Blue dotted
lines indicate cut-off for positivity. Mann-Whitney U test was used to calculate p values for differences between groups (ns=no significant difference,
*p<0.05, ****p<0.001). AU, arbitrary units; cTNC, citrullinated tenascin-C.
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a similar degree. Lack of citrullination of five other arginines in
FBG by any PAD reflects the specificity of this modification,
likely due to hindered accessibility of these residues, or
unfavourable neighbouring amino acids. Citrullinated arginines
were located at five distinct sites within FBG, of which two,
cTNC1 and cTNC5, were reactive with sera from patients with
RA. However, antibodies to only one, cTNC5, were detected in
sera of pre-RA cases.
The different associations of cTNC1 and cTNC5 suggest that
cTNC5 may be important in priming the ACPA response,
whereas antibodies to cTNC1 may arise as a result of epitope
spreading in more established disease. These data also reflect
that the autoantibody response in RA is not citrulline-specific;
instead it depends on the whole epitope around the modified
residue including neighbouring amino acids and the three-
dimensional structure.10 It is well documented that distinct
ACPA responses to different citrullinated epitopes within one
protein exist, as described for example for citrullinated
α-enolase13 or citrullinated fibrinogen.38 The peptide sequence
of cTNC5 is predicted to form a very distinct, exposed structure
at the very C-terminus of tenascin-C, potentially rendering it
more easily accessible to ACPA than cTNC1. In addition, four
sites are citrullinated within TNC5, compared with only a single
citrullinated site within cTNC1, which may also contribute to
the higher frequency of cTNC5 ACPA observed.
The frequency of anti-cTNC5 antibodies in the pre-RA
cohort (18%) is comparable to antibody frequencies described
for other ACPAs in the same cohort, including cFIBβ (18%) and
CEP-1 (15%).33 Analysis of a large cohort of patients with early
RA demonstrated moderate-to-high sensitivity of RA samples for
cTNC5 (47%). This is the highest recorded sensitivity for any
single antigenic peptide in this cohort, in this case compared
with a 35–37% sensitivity for antibodies to each of the three
other antigenic peptides.14 We also found reactivity to cTNC5
at a similar frequency (51%) in a second cohort of RA sera from
US patients.
ACPAs generally show limited cross-reactivity.14 39 In line
with these reports, we showed that antibodies to cTNC exhib-
ited little cross-reactivity with cFib, cVim and CEP-1, and are
distinct from antibodies reacting with peptides from homolo-
gous regions in fibrinogen. cTNC5 ACPA-positive sera were
mostly found within the anti-CCP2 antibody-positive RA popu-
lation with cTNC5 antibody levels highest in the anti-CCP2
antibody positive subgroup, as described for other ACPA.14 Of
the patients with RA 4.9% within the anti-CCP2 antibody-
negative group were also anti-cTNC5 ACPA-positive, demon-
strating that not all ACPA-positive patients can be detected by
testing for CCP reactivity. Moreover, a subset of CCP-positive
patients with RA was single-positive for cTNC5 antibodies
(5.4%), revealing cTNC5 as a distinct ACPA fine specificity in
RA sera and indicating that assaying this ACPA alone would be
helpful in diagnosing patients that might otherwise be missed.
Combined testing for several specific ACPAs has been shown to
increase diagnostic sensitivity and specificity.40 Together these
data suggest that the addition of cTNC5 to an assay combining
multiple ACPAs, as well as analysis of anti-cTNC5 alone, might
be beneficial approaches in diagnosing RA.
HLA-DRB1 SE alleles are associated with ACPA-positive
RA.41 We found a strong association of anti-cTNC5 antibodies
with SE positivity, as has been described for antibodies to other
citrullinated antigens, like CEP-1 and cVIM.14 15 cTNC5 anti-
bodies mainly associated with HLA-DRB1 subtypes DRB1*04
as described for other ACPAs.15 39 HLA-DR13 alleles protect
against ACPA-positive RA,42 and we show here that it is also
protective against cTNC5-positive RA. However, we did not
observe a statistical significant association of PTPN22, another
genetic risk factor for RA,43 with anti-cTNC5-positive RA.
Smoking is a well established environmental risk factor for
Figure 6 Anti-cTNC antibody levels
correlate with cyclic-citrullinated
peptide (CCP2) levels. IgG response to
cTNC5 in (A) CCP2-positive (CCP2+,
n=1255) and CCP2-negative (CCP2−,
n=730) sera of patients with
rheumatoid arthritis (RA) of the
Epidemiological Investigation of RA
(EIRA) cohort, (B) CCP2-positive
(n=240) and CCP2-negative (n=47)
sera of patients with RA of the US
cohort and (C) in CCP2-positive (n=27)
and CCP2-negative (n=74) sera of
pre-RA individuals. (D and E) Heat
maps showing the presence (blue) or
absence (red) of an IgG antibody
response to anticitrullinated protein
antibody (ACPA) epitopes in RA sera
from the EIRA cohort (D) or pre-RA
sera (E). cTNC, citrullinated tenascin-C;
RA, rheumatoid arthritis.
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ACPA-positive RA34 44 and here we describe a positive associ-
ation of cTNC5-positive RA with smoking in the EIRA cohort,
similarly as it has been described for antibodies against CEP-1
and cVIM.14 15 Smoking-induced inflammation, in the context
of chronic obstructive pulmonary disease (COPD), is associated
with enhanced citrullination and may contribute to the gener-
ation of ACPA.45 46 Interestingly, high tenascin-C expression
was detected in lungs of patients with COPD compared with
non-smokers.47 48 Another risk factor for RA, is periodontitis.49
Porphyromonas gingivalis is a major periodontal pathogen and
possesses a unique bacterial PAD enzyme which citrullinates
bacterial and endogenous host peptides.50 51 Tenascin-C is
also expressed in periodontal tissue, and tenascin-C fragments
were detected in gingival crevicular fluid of patients with peri-
odontitis.52 Our results and these studies therefore reveal poten-
tial mechanisms for the generation of antigenic cTNC peptides
in RA.
ACPAs are produced locally within the RA joint and may con-
tribute directly to disease pathogenesis.53 For example immune
complexes containing cFib stimulate cytokine synthesis in
macrophages via activation of Fcγ-receptor and TLR417 and,
due to the homology of fibrinogen and the FBG domain of
tenascin-C, it is conceivable that immune complexes containing
cTNC may contribute to disease pathogenesis through a similar
mechanism. Furthermore, citrullinated proteins themselves can
be pathogenic, as described for cFib.16 17 54 It will be interesting
to see if ACPA for cTNC5 bind to cTNC found within the RA
joint and trigger cytokine formation in the form of immune
complexes, or whether citrullination of the FBG domain
enhances its activation of TLR4.26 The citrullinated FBG
peptide previously detected in RA synovial fluid31 comprised
the sequence we found in cTNC1. However, further citrulli-
nated sites and ACPA epitopes are likely to be found in other
domains of tenascin-C, as for example in the fibronectin type-III
like repeats that share sequence homology with fibronectin, a
molecule also found in synovial fluid and which is targeted by
the autoimmune response in RA.55
The CCP-positive subset of patients with RA is linked with a
more severe disease development and worse prognosis.5 7 8
However, no association of specific ACPAs with clinical para-
meters has been described so far.56 Here, we found that cTNC5
antibodies do not correlate with a number of clinical para-
meters, however, there was a significant association of cTNC5
antibodies with disease activity (DAS28-CRP), suggesting that
cTNC5 antibodies may be a useful tool for predicting clinical
outcome.
In conclusion, we describe an immunodominant peptide from
tenascin-C, which is distinct from the other major antigenic
citrullinated peptides described to date, and at least equal if not
superior in terms of diagnostic sensitivity and specificity when
used as an antigen in ELISA. Furthermore, previous demonstra-
tions of the proinflammatory effects of tenascin-C and its detec-
tion at the site of inflammation suggest that immune responses
to the FBG domain may be important in the aetiology and
pathogenesis of RA.
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Identification of an immunodominant peptide from citrullinated tenascin-
C as a major target for autoantibodies in rheumatoid arthritis
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Supplementary Methods:
EIRA cohort
EIRA controls were randomly selected from the population registry, to match EIRA cases on age-,
gender- and residential area[1]. Smoking data was collected by questionnaire at baseline. Subjects
were categorized as ever-smokers or never-smokers[1]. HLA-DRB1 subtyping and genotyping of the
protein tyrosine phosphatase gene (PTPN22 rs2476601) was described before[2,3].
Citrullination reaction
Recombinant human FBG[4] was incubated with rabbit skeletal muscle PAD2 (rPAD2) (Sigma
Aldrich), or recombinant human PAD2 or PAD4 (hPAD2, hPAD4) (Modiquest Research) in
citrullination buffer (50 mM Tris pH 8, 150 mM NaCl, 10 mM CaCl2) with 5 mM DTT for 3, 8 or 24
hours at 37 ˚C.  1 μg of each sample was resolved on a 12% SDS gel and stained with Coomassie-blue 
or Western blotted with a monoclonal human anti-modified citrulline (AMC) antibody (Modiquest
Research, clone C4, 1:500), following chemical modification of the membrane (0.0125% FeCl3, 2.3 M
H2SO4, 1.52 M H3PO4, 0.25 M Acetic Acid, 0.25% 2, 3-butanedione monoxime, 0.125% antipyrine).
LC-MS/MS analyses
Peptides were analysed on a LC-MS/MS workflow comprising a Dionex Ultimate 3000 nLC system
coupled to a Q-Exactive mass spectrometer (Thermo Scientific) [5,6]. Briefly, chromatographic
separation was achieved using a 50cm nEASY spray column (Thermo Scientific, (PepMAP C18, 75 µm
x 500mm, 2 µm particle size) and a linear acetonitrile gradient from 2-35% in 5% DMSO and 0.1%
formic acid. Precursor peptides were detected with a resolution of 70000 at 200m/z followed by the
selection of up to 15 precursor ions. Raw data was imported into Progenesis QI (Waters,
V4.1.4832.42146) for label-free quantitation and alignment, and peptides were identified with
PEAKS (Bioinformatics Solutions, V7). The abundance of citrullinated peptides was normalised to the
abundance of their non-citrullinated counterparts, which value was further normalised to the
citrullinated peptide abundance detected in a non-citrullinated FBG control sample.
Differential Scanning Fluorimetry and Circular Dichroism
Five μM FBG was mixed with 5x SYPRO® orange protein gel stain (Life Technologies) in citrullination 
buffer and melting curves from 38 ˚C up to 99 ˚C recorded on the Applied Biosystems ViiA 7 Real-
Time PCR System (excitation 550 nm, emission, 586 nm). The melting temperature (Tm) of each
sample was defined as the maximum of the first derivate of the fluorescence. Circular dichroism
spectra of FBG samples (200 μg/ml) were recorded using a Jasco J-815 CD Spectrometer, between 
210 and 270 nm.
Peptides
Peptides from tenascin-C (accession number P24821) and fibrinogen  (P02675) and  (P02679)
chains (Table S1 and S2) were synthesized at a purity > 90-95%, with C- and N-terminal cysteines
(Pepceuticals) and solubilized in water at 10 mg/ml.  CEP-1, cVIM and cFIBβ peptides used for cross-
reactivity assays are described elsewhere[7].
Crossreactivity ELISA
Cross-reactivity was analysed in human sera that were reactive to both cTNC1 or cTNC5 and CEP-1,
cVIM, cFIBβ or citrullinated homologous fibrinogen peptides.  Sera were diluted 1:100, incubated 
with 1, 10 and 100 μg/ml of peptides for 2 hours, centrifuged at 10,000 g for 10 min and the 
supernatant added to peptide-coated plates for analysis by ELISA as described in Material and
Methods.
Statistical Analysis and Software
Mann–Whitney U tests were used to calculate p values for differences between groups (GraphPad
Prism). The 98% percentile of healthy control samples was used to define the cut-off for positive
antibody levels. Chi-square tests were used to compare frequency distributions of categorical
variables while t-tests and Wilcoxon rank-sum tests were used to compare all continuous variables.
To determine the association of smoking, HLA-DRB1 SE (subtypes DRB1*01 (except
DRB1*0103), DRB1*04 and DRB1*10), HLA-DRB1*13 and PTPN22 with different RA subsets, odds
ratios (OR) with 95% Confidence Intervals (95% CI) were calculated using unconditional logistic
regression models, with unexposed cases and controls as reference group. Analyses were adjusted
for age, gender and residential area. All analyses were performed using SAS version 9.3. Heatmaps
were generated using G-ProX and three-dimensional models were created using Pymol (Schrödinger,
LLC).
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Supplementary Table 1. Sequences of FBG peptides used for ELISAs.
FBG peptides Sequence
rTNC1 (aa 2026-2040) CVFLRRKNG-R-ENFYQNWC
cTNC1 CVFLRRKNG-cit-ENFYQNWC
rTNC2 (aa 2042-2058) CAYAAGFGD-R-REEFWLGLC
cTNC2 CAYAAGFGD-cit-REEFWLGLC
rTNC3 (aa 2091-2106) CFSVGDAKT-R-YKLKVEGYC
cTNC3 CFSVGDAKT-cit-YKLKVEGYC
rTNC4 (aa 2141-2157) CKGAFWY-R-NCH-R-VNLMGRC
cTNC4 CKGAFWY-cit-NCH-cit-VNLMGRC
rTNC5 (aa 2183-2200) CEMKL-R-PSNF-R-NLEG-R-R-KRC
cTNC5 CEMKL-cit-PSNF-cit-NLEG-cit-cit-KRC
Supplementary Table 2. Fibrinogen peptides homologous to citrullinated FBG peptides.
Fibrinogen peptides Sequence
cFIBβ281-296 CVIQN-cit-QDGSVDFG-cit-KWC
cFIBβ474-491 CWYSMRKMSMKI-cit-PFFPQQC
cFIBγ409-426 CTMKIIPFN-cit-LTIGEGQQHC
Supplementary Table 3. Association between smoking, any SE, PTPN22 and different RA subgroups
(in EIRA).
Subgroup Exposure OR (95%CI) p-value (+/+ vs +/-)
Never smokers Ever smokers
Controls 2114(43.46) 2750(56.54) 1.0 ref.
CCP2/cTNC5
-/- 85(41.87) 118(58.13) 0.86 (0.64-1.17)
-/+ 12(30.00) 28(70.00) 1.45 (0.72-2.93)
+/- 201(33.84) 393(66.16) 1.26 (1.03-1.53)
+/+ 309(27.01) 835(72.99) 1.65 (1.41-1.93) 0.0049
None SE Any SE
Controls 959(49.87) 964(50.13) 1.0 ref.
CCP2/cTNC5
-/- 94(46.31) 108(53.20) 1.15 (0.85-1.56)
-/+ 15(35.71) 27(64.29) 1.75 (0.91-3.34)
+/- 218(36.64) 368(61.85) 1.68 (1.37-2.06)
+/+ 191(16.68) 941(82.18) 4.98 (4.11-6.04) <0.0001
None PTPN22 Any PTPN22
Controls 1533(79.18) 403(20.82) 1.0 ref.
CCP2/cTNC5
-/- 126(62.07) 50(24.63) 1.65 (1.13-2.41)
-/+ 24(57.14) 12(28.57) 2.15 (1.03-4.49)
+/- 371(62.35) 136(22.86) 1.44 (1.12-1.86)
+/+ 682(59.56) 314(27.42) 1.77 (1.44-2.18) 0.08
Supplementary Table 4. Associations between DR*01, *04 and *10 and different RA subgroups with
the combination of presence or absence of CCP and cTNC5. OR were adjusted for age, gender,
residential area, smoking, alcohol consumption and other SE. NA – not analysed.
Subgroup Exposure OR**(95%CI) p-value (+/+ vs +/-)
None Any
DR*01
Controls 375(59.43) 256(40.57) 1.0ref.
CCP2/cTNC5
-/- 62(30.54) 45(22.17) 0.91(0.40-2.11)
-/+ 17(40.48) 10(23.81) NA
+/- 238(40.00) 129(21.68) 1.00(0.62-1.63)
+/+ 627(54.76) 310(27.07) 1.81(1.26-2.60) 0.01
DR*04
Controls 220(34.87) 411(65.13) 1.0ref.
CCP2/cTNC5
-/- 41(20.20) 66(32.51) 0.77(0.33-1.84)
-/+ 13(30.95) 14(33.33) NA
+/- 110(18.49) 257(43.19) 1.29(0.78-2.15)
+/+ 192(16.77) 745(65.07) 3.46(2.35-5.11) < 0.0001
DR*10
Controls 609(96.51) 22(3.49) 1.0ref.
CCP2/cTNC5
-/- 102(50.25) 5(2.46) 1.18(0.36-3.87)
-/+ 24(57.14) 3(7.14) NA
+/- 351(58.99) 16(2.69) 1.53(0.71-3.29)
+/+ 898(78.43) 39(3.41) 2.11(1.15-3.88) 0.13
Supplementary Table 5. Association between DR13 and different RA subgroups with the
combination of presence or absence of CCP and cTNC5. OR were adjusted for age, gender, residential
area, smoking, alcohol consumption and any SE.
Subgroup Exposure OR (95%CI) p-value
No DR13 Any DR13
Controls 503(79.71) 128(20.29) 1.0ref.
CCP2/cTNC5
-/- 86(42.36) 21(10.34) 0.84(0.49-1.46)
-/+ 25(59.52) 2(4.76) 0.31(0.07-1.34) (-/+ vs -/-) 0.16
+/- 315(52.94) 52(8.74) 0.67(0.47-0.97)
+/+ 867(75.72) 70(6.11) 0.30(0.22-0.42) (+/+ vs +/-) 0.0003
Supplementary Table 6. Association of cTNC5 antibodies with RA disease characteristics. Numbers in
brackets are s.d.
Characteristic
Total
(N=287)
cTNC5
positive
(N=145)
cTNC5
negative
(N=142)
p-value
Age, years 60 (12) 58 (11) 0.252
Male gender 68 58 0.084
Dis. duration, years 13 (10) 12 (9) 0.189
Swollen joints 3.9 (4.7) 3.2 (3.8) 0.212
Tender joints 3.4 (4.8) 2.9 (4.4) 0.366
Patient global (0-10) 4.5 (2.8) 3.9 (2.5) 0.067
DAS-28-CRP 4.1 (1.4) 3.8 (1.3) 0.044
Sharp score 21 (23) 17 (22) 0.061
Erosion score 5 (8) 4 (8) 0.632
Anti-CCP, U/ml 187 (123) 101 (117) <0.001
Supplementary Figure 1.
Mass spectrometry analysis of citrullinated peptides derived from the FGB domain of Tenascin C
(accession number P24821). The MS/MS spectra of tryptic peptides 2031-2041, 2042-2051, 2097-
2012, 2143-2151, 2148-2157, 2186-2192, 2186-2197, 2193-2199 and 2186-2198 are shown, where r
refers to the citrullinated position, indicating that R2033, R2050, R2098, R2147, R2151, R2187,
R2192, R2197 and R2198. The matched fragment ions of the y-type (red) and b-type (blue) are
shown. The MS/MS spectrum in the bottom panel indicates matches of predominant fragment ions
to the peptide sequence.
Supplementary Figure 2.
Relative quantitation of citrullinated peptide occurrence in FBG samples citrullinated with 2 Units of
rPAD2, hPAD2 and hPAD4 for 24 hours. (No peptide TR(+.98)YKLK was detected in the sample
citrullinated with hPAD4, however this peptide was detected when citrullinated with 20 U of
enzyme, data not shown).
Supplementary Figure 3.
Correlation of anti-cTNC5 IgG levels with IgG levels of other ACPA in RA (A) and pre-RA (B) sera.
Numbers in corners are percentage of positivity; numbers in parenthesis are percentage of positivity
within the CCP2-positive group. The dotted lines indicate cut-off for positivity.
Supplementary Figure 1
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